Intravenous Iron Drug Market to Reach $6.4 Billion by 2035

Intravenous iron drug market was valued at $3.7 billion in 2025 and is projected to reach $6.4 billion by 2035, expanding at a CAGR of 5.5% during the forecast period. Increasing prevalence of chronic kidney disease (CKD), rising iron deficiency anemia (IDA) cases, growing hospitalization rates, and expanding use of rapid iron replenishment therapies are supporting long-term market growth globally. One of the major macro drivers fueling demand for intravenous iron therapies is the increasing burden of CKD and associated anaemia worldwide. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 35.5 million U.S. adults are estimated to have chronic kidney disease. Additionally, the National Kidney Foundation states that anemia becomes increasingly common as kidney disease progresses, significantly increasing the requirement for IV iron supplementation in nephrology care settings. Rising healthcare expenditure and expanding access to infusion therapies are accelerating adoption across hospitals and specialty clinics.

Browse the full report description of “Infant Formula Ingredients Market Size, Share & Trends Analysis Report, By Ingredient Type (Proteins, Carbohydrates, Lipids & Oils, Vitamins, Minerals, Prebiotics, Probiotics, Nucleotides, Emulsifiers & Stabilizers, Specialty Functional Ingredients), By Source (Dairy-based, Plant-based, Synthetic/Bioengineered, Mixed Source), By End User (Infant Formula Manufacturers, Pediatric Nutrition Companies, Contract Manufacturers, Hospital Nutrition Suppliers), Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/infant-formula-ingredients-market

Among product types, Ferric Carboxymaltose (FCM) is emerging as the fastest-growing segment due to high-dose administration capability, lower infusion frequency, and increasing clinical adoption in heart failure-associated iron deficiency management. Hospitals and nephrology clinics continue to dominate end-user demand due to repeated iron therapy requirements among dialysis and CKD patients. The increasing use of IV iron therapies in oncology supportive care, perioperative blood management, inflammatory bowel disease-associated anemia, and postpartum anemia management is further creating strong commercial opportunities for manufacturers globally.

Key Leaders Transforming the Intravenous Iron Drug Market

• In August 2025, Viatris announced that the U.S. FDA approved Iron Sucrose Injection, USP, the first generic version of Venofer, for the treatment of iron deficiency anemia in adult and pediatric patients with chronic kidney disease. The approval included Competitive Generic Therapy designation and 180-day exclusivity for select strengths, strengthening competition and expanding affordable treatment access in the intravenous iron drug market.

• In March 2024, CSL Vifor announced that Health Canada approved Ferinject (ferric carboxymaltose) for the intravenous treatment of iron deficiency anemia in adult and pediatric patients, as well as iron deficiency in adult heart failure patients with NYHA class II/III. The approval expanded the therapeutic scope of Ferinject in Canada and strengthened CSL Vifor’s position in the global intravenous iron drug market.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Product Type
  • By Therapy Indication
  • By End-User Industry
• Competitive Landscape – Daiichi Sankyo, CSL Limited (CSL Vifor), Pharmacosmos A/S, Covis Pharma, American Regent, among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Intravenous Iron Drug Market Report Segment

By Product Type

• Ferric Carboxymaltose (FCM)
• Iron Sucrose
• Ferric Derisomaltose / Iron Isomaltoside
• Ferumoxytol
• Iron Dextran

By Therapy Indication

• Iron Deficiency Anemia (IDA)
• Chronic Kidney Disease (CKD)-Associated Anemia
• Chemotherapy-Induced Anemia
• Inflammatory Bowel Disease (IBD)-Associated Anemia
• Postpartum Anemia
• Perioperative / Surgical Blood Management
• Heart Failure-Associated Iron Deficiency

By End User

• Hospitals
• Nephrology Clinics
• Oncology Centers
• Gynecology & Obstetric Centers
• Gastroenterology Clinics
• Ambulatory Care Centers
• Others

Global Intravenous Iron Drug Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/infant-formula-ingredients-market